SELLAS Life Sciences (SLS) FCF Payout Ratio (2018)
SELLAS Life Sciences (SLS) reported FCF Payout Ratio of 0.03 for Q3 2018.
SELLAS Life Sciences (SLS) has 1 years of FCF Payout Ratio data on file, last reported at 0.03 in Q3 2018.
- Quarterly FCF Payout Ratio changed N/A year-over-year to 0.03 in Q3 2018, while the trailing twelve-month figure through Dec 2019 was 0.02 (down 72.43% YoY) and the FY2018 annual result came in at 0.02, changed N/A from the prior year.
- FCF Payout Ratio was little changed at 0.03 in Q3 2018 per SLS's latest filing.
- Across five years, FCF Payout Ratio topped out at 0.03 in Q3 2018 and bottomed at 0.03 in Q3 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.12 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -0.03 |